Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats

Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at...

Full description

Bibliographic Details
Main Authors: Amber Rath Stern, Xiaomei Yao, Yong Wang, Amanuel Berhe, Mark Dallas, Mark L. Johnson, Wei Yao, Donald B. Kimmel, Nancy E. Lane
Format: Article
Language:English
Published: Elsevier 2018-06-01
Series:Bone Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S235218721830010X
id doaj-3cd125d351134d8ba2f45f54ab52ed6f
record_format Article
spelling doaj-3cd125d351134d8ba2f45f54ab52ed6f2020-11-24T21:39:01ZengElsevierBone Reports2352-18722018-06-018115124Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic ratsAmber Rath Stern0Xiaomei Yao1Yong Wang2Amanuel Berhe3Mark Dallas4Mark L. Johnson5Wei Yao6Donald B. Kimmel7Nancy E. Lane8Engineering Systems Inc., 3310 Green Park Circle, Charlotte, NC 28217, United States; University of Missouri – Kansas City, Mechanical Engineering, 5100 Rock Hill Rd., Kansas City, MO 64110, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesUniversity of Missouri – Kansas City, School of Dentistry, 650 E 25th St, Kansas City, MO 64108, United StatesMusculoskeletal Research Unit, Department of Medicine, University of California Davis Medical Center, Sacramento, CA 95817, United StatesDepartment of Physiological Sciences, University of Florida, Gainesville, FL 32610, United StatesMusculoskeletal Research Unit, Department of Medicine, University of California Davis Medical Center, Sacramento, CA 95817, United States; Corresponding author at: Endowed Professor of Medicine and Rheumatology, Director, Center for Musculoskeletal Health, 4625 2nd Avenue, Suite 1002, Sacramento, CA 95817, United States.Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at the level of the osteocyte. This pre-clinical study determined the relationship between microstructural bone tissue properties and osteocyte lacunar size and density to strain around osteocytes with standard osteoporosis treatment or sequential therapies. Six-month-old female ovariectomized (OVX) Sprague-Dawley rats were cycled through various sequences of pharmacological treatments [alendronate (Aln), raloxifene (Ral) and human parathyroid hormone-1,34 (PTH)] for three month intervals, over nine months. Linear nanoindentation mapping was used to determine Young's modulus in perilacunar and bone matrix regions around cortical bone osteocyte lacunae. Measurements of lacunar diameter and density were completed. Treatment-related differences in Young's modulus in the perilacunar and bone matrix regions were not observed. We confirmed previous data that showed that the bone matrix region was stiffer than the perilacunar matrix region. Whole bone material properties were correlated to perilacunar matrix stiffness. Finite element models predicted a range of mechanical strain amplification factors estimated at the osteocyte across treatment groups. In summary, though the perilacunar matrix near cortical osteocyte lacuna is not as stiff as bone matrix further away, osteoporosis treatment agents do not affect the stiffness of bone tissue near osteocyte lacunae. Keywords: Lacuna, Nanoindentation, Finite element model, Sequential treatment, PTH(1-34), Alendronate, Raloxifenehttp://www.sciencedirect.com/science/article/pii/S235218721830010X
collection DOAJ
language English
format Article
sources DOAJ
author Amber Rath Stern
Xiaomei Yao
Yong Wang
Amanuel Berhe
Mark Dallas
Mark L. Johnson
Wei Yao
Donald B. Kimmel
Nancy E. Lane
spellingShingle Amber Rath Stern
Xiaomei Yao
Yong Wang
Amanuel Berhe
Mark Dallas
Mark L. Johnson
Wei Yao
Donald B. Kimmel
Nancy E. Lane
Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
Bone Reports
author_facet Amber Rath Stern
Xiaomei Yao
Yong Wang
Amanuel Berhe
Mark Dallas
Mark L. Johnson
Wei Yao
Donald B. Kimmel
Nancy E. Lane
author_sort Amber Rath Stern
title Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
title_short Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
title_full Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
title_fullStr Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
title_full_unstemmed Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
title_sort effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats
publisher Elsevier
series Bone Reports
issn 2352-1872
publishDate 2018-06-01
description Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at the level of the osteocyte. This pre-clinical study determined the relationship between microstructural bone tissue properties and osteocyte lacunar size and density to strain around osteocytes with standard osteoporosis treatment or sequential therapies. Six-month-old female ovariectomized (OVX) Sprague-Dawley rats were cycled through various sequences of pharmacological treatments [alendronate (Aln), raloxifene (Ral) and human parathyroid hormone-1,34 (PTH)] for three month intervals, over nine months. Linear nanoindentation mapping was used to determine Young's modulus in perilacunar and bone matrix regions around cortical bone osteocyte lacunae. Measurements of lacunar diameter and density were completed. Treatment-related differences in Young's modulus in the perilacunar and bone matrix regions were not observed. We confirmed previous data that showed that the bone matrix region was stiffer than the perilacunar matrix region. Whole bone material properties were correlated to perilacunar matrix stiffness. Finite element models predicted a range of mechanical strain amplification factors estimated at the osteocyte across treatment groups. In summary, though the perilacunar matrix near cortical osteocyte lacuna is not as stiff as bone matrix further away, osteoporosis treatment agents do not affect the stiffness of bone tissue near osteocyte lacunae. Keywords: Lacuna, Nanoindentation, Finite element model, Sequential treatment, PTH(1-34), Alendronate, Raloxifene
url http://www.sciencedirect.com/science/article/pii/S235218721830010X
work_keys_str_mv AT amberrathstern effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT xiaomeiyao effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT yongwang effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT amanuelberhe effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT markdallas effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT markljohnson effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT weiyao effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT donaldbkimmel effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
AT nancyelane effectofosteoporosistreatmentagentsonthecorticalboneosteocytemicroenvironmentinadultestrogendeficientosteopenicrats
_version_ 1725933147458109440